|
Report Date : |
19.11.2012 |
IDENTIFICATION DETAILS
|
Name : |
VESTA PHARMACHEM PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
B-106, 1st Floor, Gopal
Chambers, Opposite Ratan Cinema,
Salabat Pura, Surat-395 003, |
|
|
|
|
Country : |
|
|
|
|
|
Date of
Incorporation : |
03.12.2010 |
|
|
|
|
Com. Reg. No.: |
04-063134 |
|
|
|
|
Capital
Investment/ Paid-up Capital: |
Rs. 0.100 Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24230GJ2010PTC063134 |
|
|
|
|
Legal Form : |
Private limited liability company |
|
|
|
|
Line of Business
: |
Manufacturer, Exporter and Importer of Pharmaceutical Raw Materials,
Pharmaceuticals Ingredients and Advanced Pharmaceutical Intermediates. |
|
|
|
|
No. of
Employees: |
16 (Approximately) (In office 4 + In factory 12) |
RATING & COMMENTS
|
MIRA’s Rating : |
B (28) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having moderate track. The
management has failed to file its financials with the government department
since its incorporation. Mr. Vimal Ariwala, the Director has provided all details of the
subject to us. Trade relations are reported as fair. Business is active. Payments are
reported to be slow. The company can be considered for business dealings with great
caution. |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INDIAN ECONOMIC OVERVIEW
India is developing into an open-market economy, yet traces
of its past autarkic policies remain. Economic liberalization, including
industrial deregulation, privatization of state-owned enterprises, and reduced
controls on foreign trade and investment, began in the early 1990s and has
served to accelerate the country's growth, which has averaged more than 7% per
year since 1997. India's diverse economy encompasses traditional village
farming, modern agriculture, handicrafts, a wide range of modern industries,
and a multitude of services. Slightly more than half of the work force is in
agriculture, but services are the major source of economic growth, accounting
for more than half of India's output, with only one-third of its labor force.
India has capitalized on its large educated English-speaking population to
become a major exporter of information technology services and software
workers. In 2010, the Indian economy rebounded robustly from the global
financial crisis - in large part because of strong domestic demand - and growth
exceeded 8% year-on-year in real terms. However, India's economic growth in
2011 slowed because of persistently high inflation and interest rates and
little progress on economic reforms. High international crude prices have
exacerbated the government's fuel subsidy expenditures contributing to a higher
fiscal deficit, and a worsening current account deficit. Little economic reform
took place in 2011 largely due to corruption scandals that have slowed
legislative work. India's medium-term growth outlook is positive due to a young
population and corresponding low dependency ratio, healthy savings and
investment rates, and increasing integration into the global economy. India has
many long-term challenges that it has not yet fully addressed, including
widespread poverty, inadequate physical and social infrastructure, limited
non-agricultural employment opportunities, scarce access to quality basic and
higher education, and accommodating rural-to-urban migration.
|
Source
: CIA |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION PARTED BY
|
Name : |
Mr. Vimal Ariwala |
|
Designation : |
Director |
|
Contact No.: |
91-9016401819 |
|
Date : |
17.11.2012 |
LOCATIONS
|
Registered Office/ Factory 1 : |
B-106, 1st Floor,
Gopal Chambers, Opposite Ratan Cinema,
Salabat Pura, Surat-395 003, Gujarat, India |
|
Tel. No.: |
91-261-2328115 |
|
Mobile No.: |
91-9016401819 (Mr. Vimal Ariwala) |
|
Fax No.: |
91-261-6642674/ 6642675 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
1400 Sq. Ft. |
|
Location : |
Owned |
|
|
|
|
Factory 2: |
Located at Panoli, Gujarat, India |
|
Tel No.: |
91-261-6642674 |
|
Fax No.: |
91-261-2363144 |
|
Area : |
1500 Sq. Ft. |
|
Location : |
Rented |
DIRECTORS
|
Name : |
Mr. Vimal Dinesh Ariwala |
|
Designation : |
Director |
|
Address : |
9/C, Shantivan Apartment, A. M. Road, Adajan, Surat – 395009, Gujarat,
India |
|
Date of Birth/Age : |
02.09.1980 |
|
Date of Appointment : |
03.12.2010 |
|
DIN No.: |
00687902 |
|
|
|
|
Name : |
Mr. Dinesh Chandulal Ariwala |
|
Designation : |
Director |
|
Address : |
9/C, Shantivan Apartment, A. M. Road, Adajan, Surat – 395009, Gujarat,
India |
|
Date of Birth/Age : |
25.02.1955 |
|
Date of Appointment : |
03.12.2010 |
|
DIN No.: |
03086315 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 02.12.2010
|
Names of Shareholders |
|
No. of Shares |
|
|
|
|
|
Vimal Dinesh Ariwala |
|
5000 |
|
Dinesh Chandulal Ariwala |
|
5000 |
|
Total |
|
10000 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer, Exporter and Importer of Pharmaceutical Raw Materials,
Pharmaceuticals Ingredients and Advanced Pharmaceutical Intermediates. |
|
|
|
|
Products: |
·
Active Pharmaceutical Ingredients ·
Pharmaceutical Intermediates ·
Nandrolone Decanoate USP and Testosterone
Enanthate ·
Stanozolol and Oxandrolone ·
Candesartan Cilexetil, Repaglinide and Valsartan ·
Prednisolone BP and Flucticaseone Propionate BP ·
Cetirzine DiHCL and LevoCetirizine DiHCL ·
Montelukast Sodium and Desloratadine ·
Imatinib Mesylate and Gemcitabine Dihydrochloride ·
Carboplatin, Cisplatin, Oxaliplatin and
Bortezomib ·
Deferasirox, Fesoterodine and Dapoxetine HCL ·
Nalidixic Acid, Modafinil and Orlistat ·
Methandienone, Boldenone and Trenbolone Acetate ·
Deflazacort, Edaravone, Estradiol and Estrone ·
Sertraline HCL and Venlafaxine HCL ·
Sildenfil Citrate and Tadalafil ·
Resuvastatin Calcuim and Eletriptan HBR ·
Hyoscine Bytylbromite IP/BP ·
Metformine HCL and Telmisartan ·
Fluconazole and Nebivolol ·
Sibutramine HCL and Tamsulosine HCL ·
Topiramate and Pregabalin ·
Eszopiclone and Zaleplon ·
Mosapride Citrate nad Linezolid ·
Glimepiride and Pioglitazone Hyderochloride |
|
|
|
|
Export : |
|
|
Products : |
·
Raloxifene Betaxolol ·
Dextromethorphan HBR ·
Metroprolol |
|
Countries : |
Europe |
|
|
|
|
Imports : |
|
|
Products : |
Pharmaceutical Raw Material |
|
Countries : |
China |
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit (30 days) |
|
|
|
|
Purchasing : |
Cash and Credit (30 days) |
GENERAL INFORMATION
|
Suppliers : |
·
Karunesh Remedies |
|
|
|
|
Customers : |
Wholesalers, Retailers and End users ·
Lifecare Neuro Products |
|
|
|
|
No. of
Employees: |
16 (Approximately) (In office 4 + In factory 12) |
|
|
|
|
Bankers : |
Bank of |
|
|
|
|
Facilities : |
Cash Credit : Rs.1.000 Million (From Bank of Baroda) |
|
Banking
Relations : |
-- |
||||||
|
|
|
||||||
|
Auditors : |
|
||||||
|
Name : |
Brijesh Ariwala and Company Chartered Accountants |
||||||
|
|
|
||||||
|
Sister Concern : |
|
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
20000 |
Equity Shares |
Rs.10/- each |
Rs.0.200 Million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
10000 |
Equity Shares |
Rs.10/- each |
Rs.0.100
Million |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
|
Particulars |
|
|
31.03.2010 (Partnership
Firm) |
|
Sales Turnover (Approximately) |
|
|
15.000 |
|
Particulars |
|
31.03.2012 |
31.03.2011 |
|
Sales Turnover (Approximately) |
|
25.000 |
20.000 |
Expected Sales (2012-2013) : Rs.30.000 Millions
The above information has been parted by Mr. Vimal Ariwala
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
Yes |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
Yes |
|
9] |
Name of person contacted |
Yes |
|
10] |
Designation of contact
person |
Yes |
|
11] |
Turnover of firm for last
three years |
Yes |
|
12] |
Profitability for last
three years |
No |
|
13] |
Reasons for variation
<> 20% |
-- |
|
14] |
Estimation for coming
financial year |
Yes |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister
concerns |
Yes |
|
17] |
Major suppliers |
Yes |
|
18] |
Major customers |
Yes |
|
19] |
Payments terms |
Yes |
|
20] |
Export / Import details (if
applicable) |
Yes |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm
/ promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking
account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
No |
|
28] |
Incorporation details, if
applicable |
Yes |
|
29] |
Last accounts filed at
ROC |
-- |
|
30] |
Major Shareholders, if
available |
Yes |
|
31] |
Date of Birth of Proprietor/Partner/Director,
if available |
Yes |
|
32] |
PAN of
Proprietor/Partner/Director, if available |
No |
|
33] |
Voter ID No of
Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating,
if available |
No |
TRADE REFERENCES:
·
Lifecare Neuro Products
·
Karunesh Remidies
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No available
information exist that suggest that subject or any of its principals have been
formally charged or convicted by a competent governmental authority for any
financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.99 |
|
|
1 |
Rs.87.21 |
|
Euro |
1 |
Rs.70.22 |
INFORMATION DETAILS
|
Information
Gathered by : |
SLP |
|
|
|
|
Report Prepared
by : |
BSN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
2 |
|
OPERATING SCALE |
1~10 |
4 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
4 |
|
--PROFITABILIRY |
1~10 |
3 |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
3 |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
28 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.